Literature DB >> 9452787

Diagnosis of Creutzfeldt-Jakob disease and related human spongiform encephalopathies.

T Weber1, M Otto, M Bodemer, I Zerr.   

Abstract

Spongiform encephalopathies are transmissible diseases (TSE) of animals and humans. With the appearance of bovine spongiform encephalopathy (BSE) in 1986 and in 1996 with the identification of an apparently new variant of the human spongiform encephalopathy Creutzfeldt-Jakob disease (CJD), great concerns of a potential transmission of BSE to humans have been voiced. The agent known to transmit CJD and other human and animal spongiform encephalopathies is designated as prion, i.e., proteinaceous infectious agent, due to the absence of evidence for the involvement of a nucleic acid in disease transmission. In humans the clinical diagnosis of typical CJD cases can now be supported by paraclinical parameters. Electroencephalographic changes, so called periodic sharp wave complexes, are pathognomonic for CJD but by no means specific. The detection of neuronal enzymes in the cerebrospinal fluid (CSF) such as neuron specific enolase (NSE) or glial proteins such as S-100 aids greatly in the diagnosis of a human spongiform encephalopathy. By far the most specific marker in CSF are a group of proteins designated 14-3-3. Current evidence suggests that by including elevated levels of NSE (> or = 35 ng/mL), S-100 (> or = 8 ng/mL) and tau protein in the CSF and the presence of 14-3-3, a laboratory supported diagnosis of CJD can be achieved which in the appropriate clinical setting has a better diagnostic accuracy than the currently used clinical and paraclinical diagnostic criteria alone.

Entities:  

Mesh:

Year:  1997        PMID: 9452787     DOI: 10.1016/s0753-3322(97)89430-9

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

1.  A retrospective study of Creutzfeldt-Jakob disease in Belgium.

Authors:  P Pals; B Van Everbroeck; R Sciot; C Godfraind; W Robberecht; R Dom; C Laterre; J J Martin; P Cras
Journal:  Eur J Epidemiol       Date:  1999-07       Impact factor: 8.082

2.  Increased levels of epsilon and gamma isoforms of 14-3-3 proteins in cerebrospinal fluid in patients with Creutzfeldt-Jakob disease.

Authors:  H Takahashi; T Iwata; Y Kitagawa; R H Takahashi; Y Sato; H Wakabayashi; M Takashima; H Kido; K Nagashima; K Kenney; C J Gibbs; T Kurata
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

3.  Comparative peptidome analyses of the profiles of the peptides ranging from 1-10 KD in CSF samples pooled from probable sporadic CJD and non-CJD patients.

Authors:  Cao Chen; Di Xiao; Wei Zhou; Yong-Chan Zhang; Qi Shi; Chan Tian; Jin Zhang; Chun-Xi Zhou; Jian-Zhong Zhang; Xiao-Ping Dong
Journal:  Prion       Date:  2012 Jan-Mar       Impact factor: 3.931

4.  14-3-3 proteins in neurological disorders.

Authors:  Molly Foote; Yi Zhou
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

5.  Global protein differential expression profiling of cerebrospinal fluid samples pooled from Chinese sporadic CJD and non-CJD patients.

Authors:  Cao Chen; Di Xiao; Wei Zhou; Qi Shi; Hui-Fang Zhang; Jin Zhang; Chan Tian; Jian-Zhong Zhang; Xiao-Ping Dong
Journal:  Mol Neurobiol       Date:  2013-08-04       Impact factor: 5.590

6.  PrP mRNA and protein expression in brain and PrP(c) in CSF in Creutzfeldt-Jakob disease MM1 and VV2.

Authors:  Franc Llorens; Belén Ansoleaga; Paula Garcia-Esparcia; Saima Zafar; Oriol Grau-Rivera; Irene López-González; Rosi Blanco; Margarita Carmona; Jordi Yagüe; Carlos Nos; José Antonio Del Río; Ellen Gelpí; Inga Zerr; Isidre Ferrer
Journal:  Prion       Date:  2013-09-18       Impact factor: 3.931

7.  The prepared tau exon-specific antibodies revealed distinct profiles of tau in CSF of the patients with Creutzfeldt-Jakob disease.

Authors:  Cao Chen; Qi Shi; Bao-Yun Zhang; Gui-Rong Wang; Wei Zhou; Chen Gao; Chan Tian; Guo-Yong Mei; Yan-Ling Han; Jun Han; Xiao-Ping Dong
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.